TAO Synergies Inc.
TAOX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$23.61M
Close$
$2.18
30.9% downside
Current Fair Value
30.9% downsideOvervalued by 30.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $23.61 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-8.81 |
| Beta | 1.5 |
| Outstanding Shares | 7,472,200 |
Return
| Return on Equity | -168062.02% |
|---|---|
| Return on Assets | -137723.51% |
| Return on Invested Capital | -45070.90% |
Valuation & Multiples
| P/E Ratio | -0.96 |
|---|---|
| PEG | 2.06 |
| Price to Sales | - |
| Price to Book Ratio | 1.58 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-12.75
Consensus analyst estimateRevenue Estimate
$88,626
Consensus analyst estimateNext Earnings Call
Expected Date
December 2, 2026
EPS Estimate
$-12.75
Consensus analyst estimateRevenue Estimate
$88,626
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.08%▼ 9.46% |
|---|---|
| Total Invested | $25,929▼ 99.02% |
| Investors Holding | 5▼ 23.00% |
About Synaptogenix Inc
5 employees
CEO: Joshua N. Silverman
TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neuro...